HL7 Antitrust Policy

Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM).

Attendees

Please include your organization in your Zoom name.

• Click on your picture/name in Zoom
• Click on rename
• enter <name> - <organization>

Agenda Items and Notes

Outstanding Action Item List

Meeting Notes from the previous meeting

• 2023-03-13 Meeting Notes  - accepted by acclimation

Project Proposals

Project Proposals in Review - none to review

Project Scope Statements

Project Scope Statements - none to review

May WGM Draft Agenda Review

• 20 Mar 2023 - skipped

External Meeting Review

• 20 Mar 2023 - nothing to report

Catalog Updates (John Hatem)

• 20 Mar 2023 - No meeting last week

Workflow Update (John Hatem)

• 20 Mar 2023  - No update

Healthcare Product Update (John Hatem)

• 20 Mar 2023 - No update

EHR conformant reconciled medication list (cRML) (Scott Robertson / John Hatem / Jimmy Tcheng)

• 20 Mar 2023- No meeting this week, next meeting will be the first week of April. 

Project updates

Pharmacy Templates

• 20 Mar 2023 - Giorgio has a Publication request document.  It will be discussed and voted on in the March 20th meeting. 
  • Pharmacy Template STU2 - CDA Publication Request Checklist
  • HL7 CDA Pharmacy Template STU2 (publication request)
  • Based on this WG's review of the CDA Publication Checklist for this IG  (Pharmacy Template STU2 - CDA Publication Request Checklist) and confirmation that no quality variations have been detected during the performed review, a motion has been made to approve the CDA IG Publication Request.  Giorgio Cangioli / Jose Costa Teixeira: 10-0-0 

Trackers - Pharmacy Tracker Dashboard (see trackers for details / resolutions)

• 20 Mar 2023 - in good shape.  a number of things require input/work from other groups.  remaining items are minor 

Status state diagram review 

• John reviewed the mapping between Med dispense status and BDP dispense status.  Suggestion was to send this to the list serve for input. 
  • 13 Feb 2023 review of mapping document.  
    
    • "ready for pickup" (in pharmacy) compares to "allocated" in BDP.
      • BDP "allocated" description is "ready for transport"   
    • "returned" - we don't have it, do we need it (returned after picked up).  usually these are wasted ... but can be reused in some cases. 
      • as opposed to "return to stock," which was "ready for pickup" and not received by patient.
    • pharmacy "completed" - BDP says "issued"
    • pharmacy "stopped" ("failed") - BDP uses "unfulfilled".
    • pharmacy "declined" ("not-done) - maybe BDP "returned" ("abandoned")
  • 20 Mar 2023 - Need status update? 
    • John's working on it

NCPDP Updates (NCPDP Members)

20 Mar 2023 - 

Specialty Medication Enrolment IG

• 20 Mar 2023 - Need status update - have all items below been completed? 
  • STU2 Publication Request - Specialty Medication Enrollment
    • current version expires June 6, 2023
    • needs to be reviewed by FHIR Management Group
    • need to post the ballot comments spreadsheet and request withdrawal of negatives - Scott has submitted
      • https://jira.hl7.org/secure/attachment/23621/reconciliation.xls
    • Frank should be the publishing facilitator
    • #39 - should be yes
    • Provide Lynn the updated Product Brief
    • Motion to approve the publication request subject to action items above - Melva Peters - Frank McKinney - 8-0-0 Carried
    • Frank will update and forward to FMG
  • Frank reports in progress

Any Other Business

• USCDI - Shelly Spiro / Hans Buitendijk
  • 20 Mar 2023 discuss USCDI during call today - dedicate about 30 minutes for the discussion. ( Scott reached out to Hans for overview - awaiting his response)  also invite Margaret (for NCPDP side).  send note to list
    • Hans present.  extended discussion on what USCDI is, what the current (v4) goal is, how are terms defined.
      • USCDI is a set of data elements which are required for the certification of HIT systems.  currently that means that all HIT systems must be able to support all USCDI elements, even those that do not pertain to specific scenarios.  for example, Lab systems may not care about past procedures or medication instructions, but certification to USCDI would require lab systems support that information (e.g., store if received, send if present).  Comments have been submitted to the regulatory process to provide flexibility to not require all USCDI elements for all systems.
    • Medication Instructions - information to patient or care giver on how to take the medication (dose, interval, etc.).  added in v4.  Note this will initially just be a text string, but in the future should/could be fully encoded.  Maps to MedicationRequest.dosageInstruction.text (FHIR US Core v5) and MedicationDispense..dosageInstruction.text (FHIR US Core v5).
    • Medication Administration - record of mediation administrated to the patient.  mostly for inpatient and clinic-administered meds.  unlikely to be available for retail prescriptions.  group is intereste in promoting to include in v4
    • Quantity - the number of (doses) in a dispense.  As opposed to the number of dosage units in each administration.  (smr - I know we discussed this but I can't find it in USCDI).  
• Email from Floyd - pharmacy SIG questions
  • will respond to Floyd - ask him to submit a Jira issue with specific examples and the value set that is being used
  • https://childrens.health.qld.gov.au/wp-content/uploads/PDF/digital-future/qrg/Medication-scheduling-administration-times.pdf
  • 13 Mar 2023 John responded to Floyd this morning. added supplement from our discussion

Next meeting:

• 27 Mar 2023